NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry
NVIDIA announced that global pharmaceutical and techbio industry leaders are adopting its open-source BioNeMo Framework to advance drug discovery and accelerate molecule design. The framework offers accelerated computing tools to scale AI models for biomolecular research. The end-to-end platform includes NVIDIA NIM microservices and BioNeMo Blueprints for optimized workflows.
The platform features new NIM microservices supporting models like AlphaFold2 (achieving 5x speedup), DiffDock 2.0 (6.2x faster, 16% more accurate), RFdiffusion, and ProteinMPNN. Over 200 organizations are already integrating BioNeMo into their drug discovery platforms.
NVIDIA ha annunciato che i leader dell'industria farmaceutica e techbio a livello globale stanno adottando il suo framework open-source BioNeMo Framework per avanzare nella scoperta di farmaci e accelerare il design delle molecole. Il framework offre strumenti di calcolo accelerato per scalare modelli AI per la ricerca biomolecolare. La piattaforma end-to-end include microservizi NVIDIA NIM e BioNeMo Blueprints per flussi di lavoro ottimizzati.
La piattaforma presenta nuovi microservizi NIM a supporto di modelli come AlphaFold2 (che raggiunge un'accelerazione di 5 volte), DiffDock 2.0 (6,2 volte più veloce, 16% più accurato), RFdiffusion e ProteinMPNN. Oltre 200 organizzazioni stanno già integrando BioNeMo nelle loro piattaforme di scoperta di farmaci.
NVIDIA anunció que los líderes de la industria farmacéutica y techbio a nivel mundial están adoptando su framework de código abierto BioNeMo Framework para avanzar en el descubrimiento de fármacos y acelerar el diseño de moléculas. El framework ofrece herramientas de computación acelerada para escalar modelos de IA para la investigación biomolecular. La plataforma de extremo a extremo incluye microservicios NVIDIA NIM y BioNeMo Blueprints para flujos de trabajo optimizados.
La plataforma presenta nuevos microservicios NIM que apoyan modelos como AlphaFold2 (logrando una aceleración de 5x), DiffDock 2.0 (6.2x más rápido, 16% más preciso), RFdiffusion y ProteinMPNN. Más de 200 organizaciones ya están integrando BioNeMo en sus plataformas de descubrimiento de fármacos.
NVIDIA는 전 세계 제약 및 기술 생명과학 산업 리더들이 신약 발견을 추진하고 분자 설계를 가속화하기 위해 자사의 오픈소스 BioNeMo Framework를 채택하고 있다고 발표했습니다. 이 프레임워크는 생체 분자 연구를 위한 AI 모델을 확장할 수 있는 가속 컴퓨팅 도구를 제공합니다. 엔드 투 엔드 플랫폼은 최적화된 작업 흐름을 위한 NVIDIA NIM 마이크로서비스와 BioNeMo Blueprints를 포함합니다.
이 플랫폼은 AlphaFold2(5배 가속), DiffDock 2.0(6.2배 더 빠르고 16% 더 정확함), RFdiffusion, 및 ProteinMPNN과 같은 모델을 지원하는 새로운 NIM 마이크로서비스를 특징으로 합니다. 이미 200개 이상의 조직이 BioNeMo를 그들의 신약 발견 플랫폼에 통합하고 있습니다.
NVIDIA a annoncé que les leaders de l'industrie pharmaceutique et des biotechnologies au niveau mondial adoptent son framework open-source BioNeMo Framework pour faire avancer la découverte de médicaments et accélérer la conception de molécules. Le framework propose des outils de calcul accéléré pour mettre à l'échelle les modèles d'IA pour la recherche biomoléculaire. La plateforme de bout en bout comprend des microservices NVIDIA NIM et BioNeMo Blueprints pour des flux de travail optimisés.
La plateforme dispose de nouveaux microservices NIM prenant en charge des modèles tels qu'AlphaFold2 (avec un gain de vitesse de 5x), DiffDock 2.0 (6,2x plus rapide, 16% plus précis), RFdiffusion et ProteinMPNN. Plus de 200 organisations intègrent déjà BioNeMo dans leurs plateformes de découverte de médicaments.
NVIDIA gab bekannt, dass globale Führungskräfte der pharmazeutischen und technologischen Biowissenschaftsindustrie dessen Open-Source-Framework BioNeMo Framework übernehmen, um die Arzneimittelentdeckung voranzutreiben und das Moleküldesign zu beschleunigen. Das Framework bietet beschleunigte Rechenwerkzeuge zum Skalieren von KI-Modellen für die biomolekulare Forschung. Die End-to-End-Plattform umfasst NVIDIA NIM-Mikrodienste und BioNeMo Blueprints für optimierte Arbeitsabläufe.
Die Plattform bietet neue NIM-Mikrodienste, die Modelle wie AlphaFold2 (5-fach beschleunigt), DiffDock 2.0 (6,2-fach schneller, 16% genauer), RFdiffusion und ProteinMPNN unterstützen. Über 200 Organisationen integrieren bereits BioNeMo in ihre Arzneimittelentdeckungsplattformen.
- Platform achieves 5x speedup in protein structure prediction with AlphaFold2
- DiffDock 2.0 implementation shows 6.2x faster performance and 16% accuracy improvement
- Over 200 organizations already adopting the platform
- Partnership with major industry players like Genentech, Argonne National Laboratory, and AWS
- None.
Insights
The open-sourcing of NVIDIA's BioNeMo Framework represents a significant technological advancement in computational drug discovery. The platform's integration with specialized tools like NIM microservices and acceleration libraries demonstrates substantial performance improvements, including
The platform's enterprise-grade capabilities, including seamless integration with high-performance computing infrastructure and support for billion-parameter biological models, position NVIDIA to capture a larger share of the growing AI-driven drug discovery market. The collaboration with major players like Genentech, Argonne National Laboratory and AWS creates a robust ecosystem that could accelerate NVIDIA's revenue growth in the healthcare sector.
The adoption by over 200 organizations and support from global system integrators suggests strong market validation and potential for widespread implementation, strengthening NVIDIA's position in the biotech AI infrastructure space.
BioNeMo's impact on drug discovery workflows could be transformative. The platform's ability to scale AI models for biomolecular research addresses a critical bottleneck in the pharmaceutical industry - the time and computational resources required for molecular design and analysis. The improved accuracy in protein structure prediction and molecular docking could significantly reduce the failure rates in early-stage drug development.
The open-source nature of the framework democratizes access to advanced computational tools, potentially accelerating innovation across the entire biopharma sector. The integration of validated models like AlphaFold2 and DiffDock 2.0 provides researchers with industry-standard tools that have been optimized for performance, potentially reducing the time-to-market for new therapeutics.
Argonne National Laboratory, Flagship Pioneering, Terray, Weights & Biases and Dozens More Organizations Among Contributors Advancing Biomolecular Science
ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- SC24 -- NVIDIA today announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
Researchers require specialized biomolecular models and datasets that allow them to gather insights at scale to design therapeutics faster. The open-source BioNeMo Framework offers a collection of accelerated computing tools designed to exponentially scale AI models for biomolecular research, bringing a new level of supercomputing to biopharma.
“The convergence of AI, accelerated computing and expanding datasets offers unprecedented opportunities for the pharmaceutical industry, as evidenced by recent Nobel Prize wins in chemistry,” said Kimberly Powell, vice president of healthcare at NVIDIA. “To help unravel the complexities of biological systems, we’ve introduced the open-source BioNeMo Framework, which will enable researchers worldwide to accelerate the development of life-saving treatments.”
Pioneering biotech companies, techbio researchers and AI platform companies and organizations are already contributing or will contribute to the open-source framework, including A Alpha Bio; Argonne National Laboratory; Dyno Therapeutics; Genentech, a member of the Roche Group; Ginkgo Bioworks; Relation; VantAI and Weights & Biases. Key research leaders known for advancing computational science also use the BioNeMo Framework to drive innovation.
“Argonne has contributed billion-parameter biological models that require specialized software to train across high-performance computing environments,” said Arvind Ramanathan, computational science group leader at Argonne National Laboratory. “With BioNeMo, Argonne and the broader biotech community gain an enterprise-level, open-source solution that enables researchers to easily scale the training of large biological foundation models — in labs that otherwise wouldn’t have the computational expertise to do so.”
Introducing the Next-Generation BioNeMo Platform
The end-to-end NVIDIA BioNeMo platform is designed to accelerate AI model creation, customization and deployment for drug discovery and molecular design. Seamlessly integrated with accelerated computing infrastructure, it reduces costs, increases scale and speeds up drug discovery workflows to provide fast, reliable insights from biomolecular data.
In addition to the BioNeMo Framework, the platform supports NVIDIA NIM™ — optimized microservices for secure, scalable AI inference — and NVIDIA BioNeMo Blueprints, which are optimized reference designs for wet-lab and computational workflows.
NVIDIA also announced a new collection of optimized, easy-to-use NIM microservices for BioNeMo. The microservices can be deployed quickly and easily on premises or in any data center or cloud. This offers developers the flexibility to run applications across a diverse range of environments and reduces the time from inference to insights for biological drug discovery research.
The newly available NIM microservices support industry-leading models, including:
- AlphaFold2 is a deep learning model, developed by Google DeepMind, designed to transform protein structure prediction. Researchers using the AlphaFold2 NIM microservice for BioNeMo achieved a 5x speedup when predicting protein structures in near real time.
- DiffDock 2.0 is based on MIT research and trained on the gold-standard PLINDER dataset. With the DiffDock 2.0 NIM microservice, researchers were able to predict the orientation of a molecule 6.2x faster and
16% more accurately. - RFdiffusion and ProteinMPNN NIM microservices help speed up the process of designing novel proteins to bind with a target molecule and enable the creation of new protein therapeutics.
BioNeMo now includes new acceleration libraries, including cuEquivariance, that accelerate the mathematical computations essential to DiffDock predictions for chemistry.
Companies can use NVIDIA BioNeMo Blueprints, a catalog of customizable reference AI workflows, to help developers scale their AI deployments as enterprise-grade production pipelines.
The BioNeMo Blueprint for virtual screening provides a customizable, easy-to-follow workflow for using NIM microservices to design small molecules faster, while saving time and costs.
More than 200 techbios, large pharma and startup users are already integrating BioNeMo into their computer-aided drug discovery platforms and workflows.
Global system integrators, software providers and cloud service providers such as Accenture, AWS and Deloitte are bringing NVIDIA BioNeMo Blueprints to enterprises worldwide.
About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing.
For further information, contact:
Janette Ciborowski
Corporate Communications
NVIDIA Corporation
+1-734-330-8817
jciborowski@nvidia.com
Certain statements in this press release including, but not limited to, statements as to: the benefits, impact, and performance of NVIDIA’s products, services, and technologies, including NVIDIA BioNeMo Framework, NVIDIA NIM, and NVIDIA BioNeMo Blueprints; third parties using or adopting our products and technologies, the benefits and impact thereof, and the features, performance and availability of their offerings; the open-source BioNeMo Framework enabling researchers worldwide to accelerate the development of life-saving treatments; and pioneering biotech companies, techbio researchers and AI platform companies and organizations contributing to the open-source framework are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
© 2024 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, BioNeMo and NVIDIA NIM are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1e0417ca-84c4-4cf3-aa18-a5260132bcc5
FAQ
What performance improvements does NVIDIA's BioNeMo (NVDA) achieve with AlphaFold2?
How many organizations are currently using NVIDIA's BioNeMo (NVDA) platform?
What performance improvements does NVIDIA's BioNeMo (NVDA) achieve with DiffDock 2.0?
